DDInter672 DDInter1376
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Escitalopram {u} (Compound) resembles {v} (Compound) Citalopram
Escitalopram {u} (Compound) binds {v} (Gene) CYP3A4
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
Escitalopram {u} (Compound) palliates {v} (Disease) bipolar disorder
Escitalopram {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Escitalopram {u} (Compound) downregulates {v} (Gene) VAT1
Escitalopram {u} (Compound) causes {v} (Side Effect) Dysmenorrhoea
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Miconazole
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Escitalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Escitalopram (Compound) resembles Citalopram (Compound)
Escitalopram (Compound) binds CYP3A4 (Gene)
Escitalopram (Compound) upregulates RRS1 (Gene)
Escitalopram (Compound) palliates bipolar disorder (Disease)
Escitalopram (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Escitalopram (Compound) downregulates VAT1 (Gene)
Escitalopram (Compound) causes Dysmenorrhoea (Side Effect)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Miconazole
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine